The most frequent form of disease (~65% of cases) is AD (CPVT-1) and consists of mutations in the ryanodine cardiac RyR2 receptor, and the rarer form targets the cardiac calsequestrin (CASQ2) and is AR (3–5%). This evidence concerns the gene CASQ2 and catecholaminergic polymorphic ventricular tachycardia 1.